A nation-wide surveillance about the incidences and risk factors of severe and fatal thromboembolism in inflammatory bowel disease (IBD) patients in Japan.

A nation-wide surveillance about the incidences and risk factors of severe and fatal thromboembolism in inflammatory bowel disease (IBD) patients in Japan. - A nation-wide surveillance about severe and fatal thromboembolism in IBD in Japan.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000042665

Enrollment

35000

Registered

2020-12-07

Start date

2018-11-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory bowel disease (Ulcerative colitis and Crohn&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients who were diagnosed as IBD and examined in participating institutes from January 2008 to December 2017.

Exclusion criteria

Exclusion criteria: 1) The patients who declined participation to this study. 2) The patients who were judged ineligible for participating this study by the principal investigator.

Design outcomes

Primary

Measure	Time frame
The incidences of arterial and venous thromboembolism progressing to severe condition and death in IBD patients.	—

Secondary

Measure	Time frame
1) The incidence of arterial and venous thromboembolism in patients with IBD 2) The risk factors of arterial and venous thromboembolism progressing to severe condition and death in IBD patients 3) The incidences of severe and fatal thromboembolism by location of the thromboembolic lesions in IBD patients 4) The incidences of antithrombotic therapy and its hemorrhagic complications in IBD patients 5) Days from the initiation of thromboembolism to the progression of severe condition or death in IBD patients.	—

Measure

Time frame

1) The incidence of arterial and venous thromboembolism in patients with IBD 2) The risk factors of arterial and venous thromboembolism progressing to severe condition and death in IBD patients 3) The incidences of severe and fatal thromboembolism by location of the thromboembolic lesions in IBD patients 4) The incidences of antithrombotic therapy and its hemorrhagic complications in IBD patients 5) Days from the initiation of thromboembolism to the progression of severe condition or death in IBD patients.

—

Countries

Japan

Contacts

Public ContactKatsuyoshi Ando

Asahikawa Medical University Hospital Department of Medicine (Metabolism, immunology, Gastroenterology and Hematology)

k-ando@asahikawa-med.ac.jp0166-68-2462

Outcome results